Advertisement

The AAPS Journal

, 21:63 | Cite as

In Vitro Metabolism and Hepatic Intrinsic Clearance of the Synthetic Cannabinoid Receptor Agonist JWH-122 and Its Four ω-Halogenated Analogues

  • Anders Bork Davidsen
  • Marie MardalEmail author
  • Kristian Linnet
Research Article

Abstract

The number of new psychoactive substances (NPS) emerging on the illicit drug market has increased over the last decade. Halogenation of existing illicit drugs is a particular trend, with the purpose of both circumventing the law and altering the toxicodynamic and toxicokinetic profiles of the compounds. This study investigates the in vitro impact of JWH-122 ω-halogenation (fluoro, chloro, bromo and iodo) on the metabolism, apparent intrinsic hepatic clearance and analytical targets for detecting drug consumption. Metabolite profiling was conducted with pooled human liver microsomes, suspended rat hepatocytes and pooled human hepatocytes. The in vitro half-life was also determined in pooled human hepatocytes. All samples were analysed by liquid chromatography/high-resolution mass spectrometry. All compounds, except for JWH-122, showed high formation rates of phase I metabolites, predominantly ω-COOH and methylnaphthyl hydroxylation metabolites. Phase II metabolites were ω-O-glucuronides, methylnaphthyl O-glucuronides and ω-glutathione conjugates. The relative ion intensity of the glutathione conjugates increased with the ω-halogen size, with I-JWH-122 having the highest intensity. Stability studies gave a low half-life and a high intrinsic hepatic clearance for JWH-122 (1305 mL/min/kg) and MAM-2201 (1408 mL/min/kg). Cl-, Br- and I-JWH-122 showed increasing half-life with increasing ω-halogen size, with intrinsic clearance values of 235–502 mL/min/kg. The recommended analytical targets for consumption of JWH-122 or ω-halogenated JWH-122 analogues are the ω-COOH metabolites for unspecific profiling and the methylnaphthyl hydroxylated metabolites to distinguish the compounds. Furthermore, ω-halogenation with larger halogens appears to increase the intrinsic hepatic stability, thereby prolonging exposure and possibly the duration of action.

KEY WORDS

synthetic cannabinoid receptor agonist hepatocyte metabolism microsome metabolism high-resolution mass spectrometry intrinsic hepatic clearance 

Notes

Acknowledgements

The authors acknowledge Carolina Noble and Niels Bjerre Holm for their support and contribution to this work.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or laboratory animals performed by the authors.

Supplementary material

12248_2019_338_MOESM1_ESM.docx (232 kb)
ESM 1 (DOCX 231 kb)

References

  1. 1.
    European Monitoring Centre for Drugs and Drug Addiction. Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation. An update from the EU Early Warning System (June 2018). Luxembourg: Publications Office of the European Union; 2018.Google Scholar
  2. 2.
    Saito T, Namera A, Miura N. A fatal case of MAM-2201 poisoning. Forensic Toxicol. 2013;31(2):333–7.CrossRefGoogle Scholar
  3. 3.
    Derungs A, Schwaninger AE, Mansella G, Bingisser R, Kraemer T, Liechti ME. Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol. 2013;31(1):164–71.CrossRefGoogle Scholar
  4. 4.
    Roman M, Wu X, Diao X, Josefsson M, Eriksson C, Kugelberg FC, et al. 25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry. Drug Test Anal. 2016;9(5):680–98.PubMedGoogle Scholar
  5. 5.
    Lewin AH, Seltzman HH, Carroll FI, Mascarella SW, Reddy PA. Emergence and properties of spice and bath salts: a medicinal chemistry perspective. Life Sci. 2014;97(1):9–19.CrossRefGoogle Scholar
  6. 6.
    Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA. High-resolution mass spectrometry for characterizing the metabolism of synthetic cannabinoid THJ-018 and its 5-Fluoro analog THJ-2201 after incubation in human hepatocytes. Clin Chem. 2016;62(1):157–69.CrossRefGoogle Scholar
  7. 7.
    Vigolo A, Ossato A, Trapella C, Vincenzi F, Rimondo C, Seri C, et al. Novel halogenated derivates of JWH-018: behavioral and binding studies in mice. Neuropharmacology. 2015;95:68–82.CrossRefGoogle Scholar
  8. 8.
    Noble C, Cannaert A, Linnet K, Stove CP. Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors. Drug Test Anal. 2019;11(3):501–11.CrossRefGoogle Scholar
  9. 9.
    Cannaert A, Storme J, Franz F, Auwärter V, Stove CP. Detection and activity profiling of synthetic cannabinoids and their metabolites with a newly developed bioassay. Anal Chem. 2016;88(23):11476–85.CrossRefGoogle Scholar
  10. 10.
    Winstock AR, Barratt MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013;131(1–2):106–11.CrossRefGoogle Scholar
  11. 11.
    Rane A, Wilkenson GR, Shand DG. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther. 1977;200(2):420–4.PubMedGoogle Scholar
  12. 12.
    Gómez-lechón MJ, Tolosa L, Conde I, Donato MT. Competency of different cell models to predict human hepatotoxic drugs. Expert Opin Drug Metab Toxicol. 2014;10(11):1553–68.CrossRefGoogle Scholar
  13. 13.
    Castell JV, Jover R, Martnez-Jimnez CP, Gmez-Lechn MJ. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol. 2006;2(2):183–212.CrossRefGoogle Scholar
  14. 14.
    Asha S, Vidyavathi M. Role of human liver microsomes in in vitro metabolism of drugs — a review. Appl Biochem Biotechnol. 2010;160(6):1699–722.CrossRefGoogle Scholar
  15. 15.
    Di L, Keefer C, Scott DO, Strelevitz TJ, Chang G, Bi Y-A, et al. Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. Eur J Med Chem. 2012;57(6):441–8.CrossRefGoogle Scholar
  16. 16.
    Noble C, Mardal M, Bjerre Holm N, Stybe Johansen S, Linnet K. In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples. Drug Test Anal. 2017;9(8):1182–91.CrossRefGoogle Scholar
  17. 17.
    Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Huestis MA. Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. Bioanalysis. 2014;6(9):1187–200.CrossRefGoogle Scholar
  18. 18.
    Soars MG, Grime K, Sproston JL, Webborn PJH, Riley RJ. Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos. 2007;35(6):859–65.CrossRefGoogle Scholar
  19. 19.
    Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 1997;283(1):46–58.PubMedGoogle Scholar
  20. 20.
    Poulin P, Haddad S. Toward a new paradigm for the efficient in vitro–in vivo extrapolation of metabolic clearance in humans from hepatocyte data. J Pharm Sci. 2013;102(9):3239–51.CrossRefGoogle Scholar
  21. 21.
    Kim J-H, Kong TY, Moon J-Y, Choi KH, Cho Y-Y, Kang HC, et al. Targeted and non-targeted metabolite identification of MAM-2201 in human, mouse, and rat hepatocytes. Drug Test Anal. 2018;10(8):1328–35.CrossRefGoogle Scholar
  22. 22.
    Jang M, Shin I, Yang W, Chang H, Yoo HH, Lee J, et al. Determination of major metabolites of MAM-2201 and JWH-122 in in vitro and in vivo studies to distinguish their intake. Forensic Sci Int. 2014;244:85–91.CrossRefGoogle Scholar
  23. 23.
    Kong TY, Kim J-H, Choi WG, Lee JY, Kim HS, Kim JY, et al. Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes. Anal Bioanal Chem. 2017;409(6):1667–80.CrossRefGoogle Scholar
  24. 24.
    Meyer MR, Richter LHJ, Maurer HH. Methylenedioxy designer drugs: mass spectrometric characterization of their glutathione conjugates by means of liquid chromatography-high-resolution mass spectrometry/mass spectrometry and studies on their glutathionyl transferase inhibition potency. Anal Chim Acta. 2014;822:37–50.CrossRefGoogle Scholar
  25. 25.
    Sharma M, Tomasz M. Conjugation of glutathione and other thiols with bioreductively activated mitomycin C. Effect of thiols on the reductive activation rate. Chem Res Toxicol. 1994 May;7(3):390–400.CrossRefGoogle Scholar
  26. 26.
    Hutter M, Broecker S, Kneisel S, Auwärter V. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‘herbal mixtures’ using LC-MS/MS techniques. J Mass Spectrom. 2012;47(1):54–65.CrossRefGoogle Scholar
  27. 27.
    Baars AJ, Mukhtar H, Zoetemelk CEM, Jansen M, Breimer DD. Glutathione s-transferase activity in rat and human tissues and organs. Comp Biochem Physiol C Comp Pharmacol. 1981;70(2):285–8.CrossRefGoogle Scholar
  28. 28.
    Mardal M, Gracia-Lor E, Leibnitz S, Castiglioni S, Meyer MR. Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS. Drug Test Anal. 2016;8(10):1039–48.CrossRefGoogle Scholar
  29. 29.
    Liu X, Wright M, Hop CECA. Rational use of plasma protein and tissue binding data in drug design. J Med Chem. 2014;57(20):8238–48.CrossRefGoogle Scholar
  30. 30.
    Kong TY, Kim J-H, Kim DK, Lee HS. Synthetic cannabinoids are substrates and inhibitors of multiple drug-metabolizing enzymes. Arch Pharm Res. 2018;41(7):691–710.CrossRefGoogle Scholar
  31. 31.
    Teske J, Weller J-P, Fieguth A, Rothämel T, Schulz Y, Tröger HD. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography–tandem mass spectrometry. J Chromatogr B. 2010;878(27):2659–63.CrossRefGoogle Scholar
  32. 32.
    Lonati D, Buscaglia E, Papa P, Valli A, Coccini T, Giampreti A, et al. MAM-2201 (analytically confirmed) intoxication after “synthacaine” consumption. Ann Emerg Med. 2014;64(6):629–32.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  1. 1.Section of Forensic Chemistry, Institute of Forensic MedicineUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations